Cephalon, Inc.

Dupont Pharmaceuticals, Inc.

Matthew A Curry

Diane E Gingrich

Bruce D Dorsey

Karen L Milkiewicz

Benjamin J Dugan

Eugen F Mesaros

Henry Joseph Breslin

Gregory R Ott

Keith S Learn

Tao Guo

Rabindranath Tripathy

Craig A Zificsak

James L Diebold

Theodore L Underiner

Gregory J Wells

Joseph Lisko

Gulzar Ahmed

Jay P Theroff

Tho V Thieu

Rong-qiang Liu

Jason Burke

Daming Feng

Koc-Kan Ho

James Peter Beck

Linda Weinberg

Jason C Wagner

Ming You

Rong-Qiang Liu

Karen Milkiewicz

Joseph G Lisko

Jonathan Parrish

Adolph Bohnstedt

Bruce Dorsey

This application relates to compounds of the Formula I as defined herein, and/or salts thereof. This application further relates to compositions and methods of using these compounds and/or salts thereof. The compounds of Formula I are useful as ALK and JAK modulators for the treatment of proliferative disorders.

Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders

This application relates, in part, to compounds of the general Formula I and/or salts thereof, wherein X, R, R, R, R, R, and Rare as defined herein. The application also relates to compositions and methods of inhibiting at least JAK2 in subjects in recognized need thereof for the treatment of diseases or disorders for which inhibition of at least JAK2 is indicated.

Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors

This application relates to compounds of the general Formula I and salts thereof, wherein X, R, R, R, R, R, and Rare as defined herein. The application also relates to compositions and methods of treatment of hyperproliferative diseases or disorders.

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders. 

Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors

The present invention describes novel benzimidazoles of formula: ##STR1## or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Benzimidazoles as corticotropin release factor antagonists

Growing community of inventors

Coatesville, PA, United States of America

Matthew A Curry